Critical issues in head and neck oncology key concepts from the Eighth THNO Meeting
This is an open access book. With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics...
| Otros Autores: | , , , , , |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Cham :
Springer International Publishing
2023.
|
| Edición: | 1st ed. 2023. |
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009741106506719 |
Tabla de Contenidos:
- The gut microbiota and anticancer immunotherapy, Laurence Zitvogel
- The bidirectional communication between tumor cells and other components of the tumor microenvironment, Phil Sloan
- Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this, Kirsten Lauber
- DNA repair mechanisms as a new target in head and neck cancer, Kevin Harrington
- How to standardize molecular profiling programs for routine patient care, Ingeborg Tinhofer
- Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau
- Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches, Ben O’Leary
- Clinical cases, Jean Pascal Machiels
- Updates from the European Head & Neck Society (EHNS), Wojciech Golusinski (President of EHNS) Section 2: Primary disease Piero Nicolai
- Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neck cancer, Brian O’Sullivan
- From photon to proton: what’s in it for head and neck cancer patients?, Volker Budach
- Lessons learned from RTOG 1016 and DE-ESCALaTE: what’s next?, Hisham Mehanna.-Treatment intensification in LA-SCCHN: what are the options and for who?, Jan Vermorken
- Immune checkpoint inhibitors in the curative setting: preclinical and clinical data, Jean-Pascal Machiels
- Carcinoma of unknown primary: diagnostics and the potential of transoral surgery, René Leemans
- Clinical cases, Volker Budach
- Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?, Petr Szturz
- Patterns of response to immune oncology drugs: how relevant are they in SCCHN?, Amanda Psyrri
- The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN, Daan Nevens
- Updates from the EORTC Head and Neck Cancer Group (HNCG), Jean-Pascal Machiels (Chair of EORTC-HNCG)
- Real world evidence in head and neck cancer, Anil D’Cruz (UICC president
- Pathology driven treatment of skull base tumors, Piero Nicolai
- Modern day reconstruction of facial bones, Sat Parmar
- Targeting molecular/minimal residual disease using novel technologies and clinical trials design, Lillian Siu
- New developments in surgery for malignant salivary gland tumors, Jeroen Meulemans
- New systemic therapies in salivary gland cancer, Ethan Argiris. Exercise and nutrition interventions in head and neck cancer, Paolo Bossi
- Telehealth intervention in head and neck cancer patients: a promise?, Irma Verdonck-de Leeuw.
